Bone Biologics Corporation (BBLG)
$0.29
Rating:
Recommendation:
-
| Symbol | BBLG |
|---|---|
| Price | $0.29 |
| Beta | 0.340 |
| Volume Avg. | 0.30M |
| Market Cap | 4.438M |
| Shares () | - |
| 52 Week Range | 0.178-4.07 |
| 1y Target Est | - |
| DCF Unlevered | BBLG DCF -> | |
|---|---|---|
| DCF Levered | BBLG LDCF -> | |
| ROE | -63.76% | Strong Sell |
| ROA | -49.14% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 18.16% | Neutral |
| P/E | - | |
| P/B | 0.68 | Buy |
Latest BBLG news
About
Download (Excel)Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.